Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II

Journal of Crohn's and Colitis

Volumn 3, Issue 4, 2009, Pages 232-240

  Michetti, Pierre ^a   Stelle, Marc ^a   Juillerat, Pascal ^a,e   Gassull, Miquel ^b   Heil, Franz Josef ^c   Stange, Eduard ^d   Mottet, Christian ^a   Gonvers, Jean Jacques ^a   Pittet, Valérie ^e   Vader, John Paul ^e   Froehlich, Florian ^a,f   Felley, Christian ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Robert Bosch Krankenhaus ^*

^d ROBERT BOSCH HOSPITAL   (Germany)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Anti TNF; ; Azathioprine; ; Crohn's Disease; ; Methotrexate; ; Pegol; Steroids; ; Therapy;

Indexed keywords

ADALIMUMAB; BUDESONIDE; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ARTICLE; CROHN DISEASE; DISEASE SEVERITY; HUMAN; PRIORITY JOURNAL;

EID: 70350581892     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.05.003     Document Type: Article

References (54)

1. Cohen R.D. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 16 9 (2002) 1603-1609
2. Hanauer S.B., and Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 96 3 (2001) 635-643
3. Summers R.W., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 4 Pt 2 (1979) 847-869
4. Malchow H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 2 (1984) 249-266
5. Hanauer S.B., and Stromberg U. Efficacy of oral Pentasa (R) 4 g/day in treatment of active Crohn's disease: a meta-analysis double-blind, placebo-controlled trials. Gastroenterology 120 5 (2001) 2308
6. Campieri M., et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 2 (1997) 209-214
7. Rutgeerts P., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 331 13 (1994) 842-845
8. Kane S.V., et al. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 16 8 (2002) 1509-1517
9. Faubion Jr. W.A., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 2 (2001) 255-260
10. Munkholm P., et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 3 (1994) 360-362
11. van Dullemen H.M., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 1 (1995) 129-135
12. Cohen R.D., Tsang J.F., and Hanauer S.B. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95 12 (2000) 3469-3477
13. Farrell R.J., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.[comment]. Am J Gastroenterol 95 12 (2000) 3490-3497
14. Hanauer S.B., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359 9317 (2002) 1541-1599
15. Sandborn W.J., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99 (2004) 1984-1989
16. Papadakis K.A., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100 1 (2005) 75-79
17. Hinojosa J., et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 25 4 (2007) 409-418
18. Colombel J.F., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 1 (2007) 52-65
19. Sandborn W.J., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 12 (2007) 829-838
20. Winter T.A., et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 20 11-12 (2004) 1337-1346
21. Schreiber S., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 3 (2005) 807-818
22. Sandborn W.J., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 3 (2007) 228-238
23. Colombel J., et al. Certoluzimab pegol administered subcutaneously is effective in anti-TNF naive patients and in patients previously treated with infliximab. Gut 55 suppl (2006) A21
24. Macdonald J., and McDonald J. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 1 (2007) CD006097
25. Fernandez-Banares F., et al. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 19 5 (1995) 356-364
26. Griffiths A.M., et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 108 4 (1995) 1056-1067
27. Messori A., et al. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 31 3 (1996) 267-272
28. Candy S., et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 5 (1995) 674-678
29. Ewe K., et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. [comment]. Gastroenterology 105 2 (1993) 367-372
30. Present D.H., et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302 18 (1980) 981-987
31. Rhodes J., et al. Controlled trial of azathioprine in Crohn's disease. Lancet 2 7737 (1971) 1273-1276
32. Willoughby J.M., et al. Controlled trial of azathioprine in Crohn's disease. Lancet 2 7731 (1971) 944-947
33. Klein M., et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 66 5 (1974) 916-922
34. Pearson D.C., et al. Azathioprine and 6-Mercaptopurine in Crohn Disease-a metaanalysis. Ann Intern Med 123 2 (1995) 132-142
35. Oren R., et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 92 12 (1997) 2203-2209
36. Arora S., et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 46 27 (1999) 1724-1729
37. Feagan B.G., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.[comment]. N Engl J Med 332 5 (1995) 292-297
38. Cohen R.D. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 7 Suppl 1 (2001) S17-S22
39. Hommes D.W., et al. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 8 2 (2002) 81-86
40. Ricart E., et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96 3 (2001) 722-729
41. Rutgeerts P., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 2 (2004) 402-413
42. Panis Y. Surgical management of patients with inflammatory bowel disease: consensus and controverse. Gastroenterol Clin Biol 27 3 Suppl (2003) S92-S97
43. Michetti P., et al. Therapy of mild to moderate luminal Crohn's disease. Digestion 71 1 (2005) 13-18
44. Michetti P., et al. Severe and steroid-resistant Crohn's disease. Digestion 71 1 (2005) 19-25
45. Naylor C.D. What is appropriate care?. N Engl J Med 338 26 (1998) 1918-1920
46. Vader J.P., et al. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach-EPACT. Digestion 73 4 (2006) 237-248
47. Juillerat P., et al. EPACT II: project and methods. Digestion 76 2 (2007) 84-91
48. Brook R.H., et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 2 1 (1986) 53-63
49. Benchimol E.I., et al. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 1 (2009) CD002913
50. Travis S.P., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
51. Colombel J., et al. Sonic: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathiprine to azathioprine to patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 57 suppl II (2008) A1 (abstract no OP0001)
52. Candy S., et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37 5 (1995) 674-678
53. Schreiber S., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 3 (2007) 239-250
54. D'Haens G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 9613 (2008) 660-667